Identifying the Optimal CSU Patient Population for Remibrutinib

Jason Hawkes, MD, MS, a board-certified dermatologist and associate professor of Dermatology at the University of California Davis, notes that, unlike omalizumab, for which IgE levels may predict response, remibrutinib and dupilumab demonstrate efficacy irrespective of baseline IgE concentrations. This widens their applicability to both IgE-dependent and IgE-independent CSU populations, as well as those who have failed other therapies.

Despite these advances, Hawkes emphasizes the current lack of robust biomarkers or clinical predictors for individual response to BTK inhibitors and other novel agents in CSU. He stresses the ongoing need for further research to address this knowledge gap and optimize precision medicine approaches within the field.

Until more definitive markers are established, Hawkes encourages clinicians to focus primarily on reducing patient disease burden and improving quality of life, using available therapies judiciously and empirically while remaining alert for future evidence that could refine patient selection.